30 results about "Esophageal disease" patented technology

A method for treating Barrett's esophagus and esophageal cancer by using non-thermal electroporation energy to ablate diseased portions of the esophagus which, in effect, prevents stomach acids and other fluids from entering the esophagus thereby alleviating continued deterioration of the esophagus and allows the columnar cells in the lining of the esophagus to assume their normal physical characteristics and functions and.

The methods and apparatus of the present invention allow the evaluation of inflammation of the esophagus. Measurements may be utilized, for example, to diagnose a disease of the esophagus, to monitor inflammation of the esophagus, or to access the treatment of a disease of the esophagus. In one embodiment, the invention comprises a method for measuring esophageal inflammation comprising deploying a device into the esophagus of a subject, removing the device after a predetermined period of time, analyzing the device for a diagnostic indicator of esophageal inflammation and evaluating the diagnostic indicator to diagnose esophageal inflammation.

The invention discloses a capsule endoscope for examining esophageal diseases. The capsule endoscope comprises a capsule shell, an imaging device, a control device, an air bag, an inflation/deflation device connected with the air bag, and a pressure sensor, wherein the air bag is transparent and arranged on the periphery of the capsule shell, the inflation/deflation device and the pressure sensor are both arranged in the capsule shell, the inflation/deflation device is used for driving the air bag to be opened or contracted, and the pressure sensor is used for measuring the pressure of air in the air bag. According to the capsule endoscope, the size of the air bag can be controlled through the inflation/deflation device according to the pressure or peristalsis force of the esophagus wall, so that sufficient contact between the air bag and the esophagus wall is achieved, the moving speed of capsules is reduced, the esophagus is stretched, and then the image or video of the esophagus wall can be acquired easily and the lesion part of the esophagus wall can be treated.

The invention provides a filament tube capsule oesophagoscope capable of being released and magnetically controlled. The filament tube capsule oesophagoscope capable of being released and magnetic controlled comprises a needle cylinder, a filament tube, a vacuum sucking disc and a capsule endoscope. The filament tube capsule oesophagoscope capable of being released and magnetic controlled is characterized in that one end of the filament tube is connected with the needle cylinder, the other end of the filament tube is connected with the vacuum sucking disc, and the capsule endoscope is a micro-camera with magnetic dipoles. According to the filament tube capsule oesophagoscope capable of being released and magnetic controlled, the speed of the capsule endoscope passing through an esophagus is controlled through the filament tube and the vacuum sucking disc, viewing angles of the capsule endoscope can be controlled freely, and the defects that a common capsule endoscope is short in dwelling time in the esophagus, high in a missing rate, single in viewing angles and the like are overcome. The filament tube capsule oesophagoscope capable of being released and magnetic controlled is simple in structure, low in cost, convenient to use and capable of greatly improving a detectable rate of esophageal diseases after being popularized and used.

Devices, systems, and methods for treating gastro-esophageal reflux disease (GERD) include anti-reflux valves and retainers for securing them within the lumen of the esophagus, stomach, or a hiatal hernia. The retainers contain inflatable balloons, some of which may be enveloped by a flexible shell that is used to secure the balloon to tissue. Methods are described for treating GERD patients who (1) have no hiatal hernia, (2) have a hiatal hernia that is fixed in place, or (3) have a hiatal hernia that slides above and below the diaphragm. Methods are also described for delivering GERD-treatment devices to their target locations within the patient's gastrointestinal tract.

The invention relates to the technical field of medical assistance, in particular to an esophageal cancer preoperative management method and system based on artificial intelligence. The system comprises a client and a server. The server comprises a case typical picture library, a picture pattern recognition module, a high-risk lesion target recognition module, a surface blood vessel typing recognition module and an AVA segmentation recognition module. According to the method, a plurality of deep learning models (relating to image classification, target detection and semantic segmentation) areconstructed according to different tasks, a cascaded model fusion technology is adopted, and a full-process intelligent auxiliary diagnosis function is provided in the esophageal disease screening process of an endoscopic doctor. The esophagus high-risk focus is detected in the NBI distant view mode, and AB typing and AVA typing are observed according to endoscopic examination, so that doctors canbe helped to better and accurately evaluate the illness state of a patient, and more scientific treatment options are provided.

The invention belongs to the field of biomedical engineering and specifically relates to an esophageal tissue constructed by tissue engineering. A tissue-engineered esophagus containing an epithelial layer and a dermal layer is consisted of scaffold materials and seed cells according to the basic principles and methods of tissue engineering. Vascular endothelial cells in the dermal layer directly participate in the establishment of a capillary network, and two revascularization methods are used to quickly communicate the capillary network in the dermal layer with the blood supply channel of a receptor, thus providing blood to the epithelium of the tissue-engineered esophagus. The esophageal tissue of the invention changes a former therapeutic mode of repairing damage by damage, and can be used for simplifying esophagectomy and one-stage reconstruction of digestive tracts, thus reducing medical trauma and benefiting the majority of patients with esophageal diseases.

The invention discloses traditional Chinese chinese preparation for treating gastro-esophageal reflex disease. Raw materials include, by weight part, from 10 to 15 parts of inula flower, from 5 to 10 parts of ruddle, from 10 to 15 parts of dry radix ginseng, from 5 to 10 parts of rhizoma pinelliae preparata, from 5 to 10 parts of radix glycyrrhizae preparate, from 12 to 18 parts of Sichuan coptischinensis, from 3 to 6 parts of fructus evodiae, from 15 to 20 parts of western tangkuei, from 10 to 15 parts of loquat leaves and from 1 to 3 parts of bitter platycodon grandiflorum. Efficiency of the traditional Chinese medicine preparation reaches 92.7%, and a good curative effect is obtained.

The present invention relates to compositions comprising at least one film-forming agent able to adhere in a stable way to the mucosa of the mouth, esophagus and upper airways, establishing a mechanical form of protection against attack on said mucosae. Said compositions are useful in the prevention and/or treatment of disorders of the oral cavity, esophagus and upper airways caused by bacterial and/or viral agents and/or by chemical agents.

The invention belongs to the technical field of cell engineering, and particularly discloses a method for constructing a mammalian esophageal squamous epithelial immortalized cell line, the constructed cell line and an organoid cultured by the constructed cell line. The construction method comprises the following steps of: taking primary esophageal squamous epithelial cells as host cells, infecting the host cells by cDNA (hTERT cDNA) retrovirus containing hTERT genes, and screening by selecting a culture medium to obtain the immortalized 'normal' cell line. Meanwhile, the cell line can be cultured into a normal esophageal squamous epithelial organoid, and provides a research basis for researching development and growth of mammalian esophagus, stem cell maintenance, epithelial proliferation and differentiation homeostasis and esophageal diseases, particularly pathogenesis and therapeutic drug research and development of esophageal squamous carcinoma (ESCC).

The invention relates to a Chinese herbal medicinal composition for treating atrophic gastritis and a preparation method thereof. The Chinese herbal medicinal composition consists of a medicine A and a medicine B which are alternately used, wherein the medicine A comprises the following Chinese herbs: dandelion, camptotheca acuminata, tripterygium hypograucum, herba patriniae and hedyotis diffusa; and the medicine B comprises the following Chinese herbs: groundsel, dandelion and tripterygium hypograucum. The Chinese herbal medicinal composition has the advantages as follows: the Chinese herbal medicinal composition is formulated from the Chinese herbs, most of which have the effects of smoothening Qi, stopping pains, clearing heat and toxic materials, regulating the liver and the stomach, mainly eliminating toxicity, removing stasis, regulating the body immunity to be stable, regulating the liver and the stomach, eradicating esophageal diseases and accelerating gastric mucosa regeneration; after the Chinese herbal medicinal composition is used, the Chinese herbal medicinal composition takes effect fast and can quickly relieve pains of a patient; and after treatment, the incidence of the atrophic gastritis is low and the therapeutic effect is consolidated.

The present invention provides an agent for the prophylaxis or treatment of visceral pain associated with gastrointestinal tract diseases, which contains lysine. Using the prophylactic or therapeutic agent, gastrointestinal tract diseases accompanying visceral pain, such as intestinal disorder, irritable bowel syndrome, functional dyspepsia, gastro esophageal disease, functional abdominal pain syndrome, ulcerative colitis and Crohn's disease and the like can be lo treated or prevented. In addition, pharmaceutical agent, food and drink and dietary supplement for the prophylaxis or treatment of visceral pain associated with such gastrointestinal tract diseases are provided. They are highly effective for visceral pain associated with gastrointestinal tract diseases as compared to existing pharmaceutical agents, show reduced side effects, and are highly effective.

The present disclosure provides a composition comprising Lidocaine or salt or hydrate or solvate thereof, L-Carnosine or salt or hydrate or solvate thereof and dexpanthenol or salt or hydrate or solvate thereof. The composition may further comprise one or more other active agents. In an embodiment, the composition is formulated as an oral formulation. The compositions of the present disclosure may find utility in treatment of oral mucositis, ulcers, ulcer mediated pain and the like conditions. Aspects of the present disclosure also relates to method of treating oral, pharyngeal, oropharyngeal and esophageal diseases or conditions using the advantageous compositions of the present disclosure.

The invention discloses a preparation method of a traditional Chinese medicine composition for treating chronic benign gastropathy and esophageal diseases. The preparation method comprises the following steps: (1) preparing a culture medium: proportionally preparing the traditional Chinese medicine composition for treating the chronic benign gastropathy and esophageal diseases, putting the traditional Chinese medicine composition into a culture container, and adding sterile water, bran and sweet wormwood herb to the culture container; (2) sterilization; (3) inoculation: taking out the culturecontainer from a sterilization container, and inoculating edible and medicinal aspergillus CICC41649; (4) fermentation: carrying out static culture on the inoculated traditional Chinese medicine composition in a fermentation device at 29-31 DEG C for 4-9 days until the fermentation is completed; and (5) decoction: carrying out decoction to obtain a liquid medicine product. Microorganisms are introduced in the preparation process, the absorption rate of the medicine is increased, the toxic and side effects of the medicine are reduced, and the curative effect of the medicine is enhanced.

The invention discloses a traditional Chinese medicine composition for treating chronic benign stomach diseases and esophageal diseases. The traditional Chinese medicine composition is characterized by being prepared from the following raw medicinal materials in parts by weight: 8-12 parts of codonopsis pilosula, 8-12 parts of roasted rhizoma atractylodis macrocephalae, 8-12 parts of poria cocos,4-8 parts of fingered citron, 4-8 parts of immature bitter orange, 4-8 parts of hovenia dulcis thunb, 4-8 parts of sea-buckthorn, 4-8 parts of perilla leaves, 4-8 parts of smoked plum, 4-8 parts of seville orange flower, 4-8 parts of ginger processed pinellia and 8-12 parts of liquorice. The stomach diseases and esophageal diseases caused by insufficient secretion of gastric acid and digestive enzyme can be effectively treated by selecting targeted traditional Chinese medicine components.

The invention discloses a traditional Chinese medicinal composition for treating upper respiratory tract and esophageal diseases, as well as a preparation and application thereof. The traditional Chinese medicinal composition is prepared from the following raw medicaments in parts by weight: 5 to 15 parts of rhizoma pinelliae preparatum, 5 to 15 parts of barks, root barks and branch roots of mangnolia officinalis, 10 to 20 parts of poria cocos, 1 to 5 parts of gingers, 5 to 15 parts of caulis perillae, 5 to 15 parts of red dates, 5 to 15 parts of roots of scutellaria baicalensis, 5 to 15 parts of whole grass of dandelion and 5 to 15 parts of nuts of areca catechu. The traditional Chinese medicinal composition has comprehensive efficacy and extremely good targeted curative effects on the upper respiratory tract and esophageal diseases, and is verified by clinical application to have definite curative effects, mild properties, no toxic or side effects and adverse reactions, and a high safety coefficient.

The medicine-containing bamboo joint type esophageal stent is formed by combining a hollow columnar structure, annular structures at the two ends and outer wall umbrella-shaped protruding structures, the outer wall umbrella-shaped protruding structures are spaced by a certain distance, and a certain included angle is formed between each outer wall umbrella-shaped protruding structure and the outer wall of the hollow columnar structure. The hollow cylindrical structure can isolate the contact between the esophageal contents and the esophageal wall. The inner surface of the hollow columnar structure is smooth, so that fluid food can smoothly pass through. The medicine-containing bamboo joint type esophageal stent comprises the polymer, the pore-foaming agent and the medicine, can stay in the esophagus for a long time, releases the medicine for a long time, treats esophageal diseases and prevents the problem of esophageal stenosis caused by esophageal cell hyperplasia.